Page 845 - Cardiac Nursing

/
0
0
9
9
/
6
2
2
009
6
/
/
9
22.
22.
22.
9-8
9-8
9-8
qx
d
2
2
qx
qx
d
009
e 8
e 8
21
Pa
g
g
21
ar
a
a
Apt
Apt
ar
Pa
8:
8:
8:
009
0
0
5
M
M
Pa
5
9 P
9 P
5
5
3
3
p79
p79
_
_
3
LWB
K34
LWBK340-c35_p799-822.qxd 29/06/2009 08:59 PM Page 821 Aptara
LWB
0-c
0-c
K34
K34
C HAPTER 35 / Hypertension 821
153. Somes, G. W., Pahor, M., Shorr, R. I., et al. (1999). The role of diastolic 173. Dargie, H. J. (2001). Effect of carvedilol on outcome after myocardial
blood pressure when treating isolated systolic hypertension. Archives of infarction in patients with left-ventricular dysfunction: The CAPRI-
Internal Medicine, 159, 2004–2009. CORN randomised trial. Lancet, 357(9266), 1385–1390.
9
9
7
7
154. Bakris, G. L., Gaxiola, E., Messerli, F. H., et al., for the INVEST Inves- 174. Pitt, B., Remme, W., Zannad, F., et al. (2003). Eplerenone, a selective al-
tigators. (2004). Clinical outcomes in the diabetes cohort of the Interna- dosterone blocker, in patients with left ventricular dysfunction after my-
tional Verapamil SR-Trandolapril study. Hypertension, 44, 637–642. ocardial infarction. New England Journal of Medicine, 348(14), 1309–1321.
4
4
155. Copley, J. B., & Rosario, R. (2005). Hypertension: A review and ration- 175. Yusuf, S., Sleight, P., Pogue, J., et al. (2000). Effects of an angiotensin-
ale for treatment. Disease Management, 51, 548–614. converting-enzyme inhibitor, ramipril, on cardiovascular events in high-
156. Sawicki, P. T., & McGauran, N. (2006). Have ALLHAT, ANBP2, AS- risk patients. The Heart Outcomes Prevention Evaluation Study Investi-
COT-BPLA and so forth improved our knowledge about better hyper- gators. New England Journal of Medicine, 342(3), 145–153.
8
tension control? Hypertension, 48, 1–7. 176. Dahlof, B., Devereux, R. B., Kjeldsen, S. E., et al. (2002). Cardiovascu-
157. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative lar morbidity and mortality in the Losartan Intervention For Endpoint
Research Group. (2002). Major outcomes in high-risk hypertensive patients reduction in hypertension study (LIFE): A randomised trial against
randomized to angiotensin-converting enzyme inhibitor or calcium-channel atenolol. Lancet, 359(9311), 995–1003.
9
9
blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to 177. Black, H. R., Elliott, W. J., Grandits, G., et al. (2003). Principal results
Prevent Heart Attack Trial (ALLHAT). JAMA, 288(23), 2981–2997. of the Controlled Onset Verapamil Investigation of Cardiovascular End
158. Wing, L. M., Reid, C. M., Ryan, P., et al. (2003). A comparison of outcomes Points (CONVINCE) trial. JAMA, 289(16), 2073–2082.
W
W
with angiotensin-converting–enzyme inhibitors and diuretics for hyperten- 178. Arauz-Pacheco, C., Parrott, M. A., & Raskin, P. (2003). Treatment of hy-
6
sion in the elderly. New England Journal of Medicine, 348(7), 583–592. pertension in adults with diabetes. Diabetes Care, 26(Suppl. 1), S80–S82.
6
159. Dahlof, B., Sever, P. S., Poulter, N. R., et al. (2005). The Anglo-Scandana- 179. Efficacy of atenolol and captopril in reducing risk of macrovascular and
vian Cardiac Outcomes Trial—Blood Pressure Lowering Arm (ASCOT- microvascular complications in type 2 diabetes: UKPDS 39. UK
7
6
7
BPLA): A multicentre randomized controlled trial. Lancet, 366, 895–906. Prospective Diabetes Study Group. (1998). BMJ, 317(7160), 713–720.
6
160. Frohlich, E. D. (2003). Treating hypertension-what are we to believe? 180. Lewis, E. J., Hunsicker, L. G., Bain, R. P., et al. (1993). The effect of an-
New England Journal of Medicine, 348(7), 639–641. giotensin-converting-enzyme inhibition on diabetic nephropathy. The
161. Hunt, S. A., Baker, D. W., Chin, M. H., et al. (2001). ACC/AHA guide- Collaborative Study Group. New England Journal of Medicine, 329(20),
9
9
lines for the evaluation and management of chronic heart failure in the 1456–1462.
adult: Executive summary. A report of the American College of Cardiol- 181. Brenner, B. M., Cooper, M. E., de Zeeuw, D., et al. (2001). Effects of losar-
ogy/American Heart Association Task Force on Practice Guidelines tan on renal and cardiovascular outcomes in patients with type 2 diabetes
5
5
(Committee to revise the 1995 Guidelines for the Evaluation and Man- and nephropathy. New England Journal of Medicine, 345(12), 861–869.
agement of Heart Failure). Journal of the American College of Cardiology, 182. Lewis, E. J., Hunsicker, L. G., Clarke, W. R., et al. (2001). Renoprotec-
38(7), 2101–2113. tive effect of the angiotensin-receptor antagonist irbesartan in patients
162. Tepper, D. (1999). Frontiers in congestive heart failure: Effect of Meto- with nephropathy due to type 2 diabetes. New England Journal of Medi-
prolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised cine, 345(12), 851–860.
Intervention Trial in Congestive Heart Failure (MERIT-HF). Congestive 183. Randomised placebo-controlled trial of effect of ramipril on decline in
Heart Failure, 5(4), 184–185. glomerular filtration rate and risk of terminal renal failure in proteinuric,
163. Packer, M., Coats, A. J., Fowler, M. B., et al. (2001). Effect of carvedilol non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi
on survival in severe chronic heart failure. New England Journal of Med- Epidemiologici in Nefrologia). (1997). Lancet, 349(9069), 1857–1863.
4
icine, 344(22), 1651–1658. 184. Wright, J. T., Jr., Agodoa, L., Contreras, G., et al. (2002). Successful
4
W
W
164. A randomized trial of beta-blockade in heart failure. The Cardiac Insuf- blood pressure control in the African American Study of Kidney Dis-
ficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. ease and Hypertension. Archives of Internal Medicine, 162(14),
(1994). Circulation, 90(4), 1765–1773. 1636–1643.
R
165. Effect of enalapril on survival in patients with reduced left ventricular 185. PROGRESS Collaborative Group. (2001). Randomised trial of a
R
ejection fractions and congestive heart failure. The SOLVD Investigators. perindopril-based blood-pressure-lowering regimen among 6,105 indi-
(1991). New England Journal of Medicine, 325(5), 293–302. viduals with previous stroke or transient ischaemic attack. Lancet,
166. Effect of ramipril on mortality and morbidity of survivors of acute my- 358(9287), 1033–1041.
ocardial infarction with clinical evidence of heart failure. The Acute In- 186. Julius, S., Nesbitt, S. D., Egan, B. M., et al. (2006). Trial of Preventing
farction Ramipril Efficacy (AIRE) Study Investigators. (1993). Lancet, Hypertension (TROPHY) investigators. Feasibility of treating prehyper-
342(8875), 821–828. tension with an angiotensin-receptor blocker. New England Journal of
4
4
167. Kober, L., Torp-Pedersen, C., Carlsen, J. E., et al. (1995). A clinical trial Medicine, 354, 1685–1697.
of the angiotensin-converting-enzyme inhibitor trandolapril in patients 187. Mancia, G., De Backer, G., Dominiczak, A., et al. (2007). Guidelines for
with left ventricular dysfunction after myocardial infarction. Trandolapril the management of arterial hypertension: The task force for the manage-
Cardiac Evaluation (TRACE) Study Group. New England Journal of ment of arterial hypertension of the European Society of Hypertension
Medicine, 333(25), 1670–1676. (ESH) and of the European Society of Cardiology (ESC). Journal of Hy-
5
5
168. Cohn, J. N., & Tognoni, G. (2001). A randomized trial of the an- pertension, 25, 1105–1187.
giotensin-receptor blocker valsartan in chronic heart failure. New Eng- 188. Lindholm, L. H., Carlberg, B., & Samuelsson, O. (2005). Should beta-
land Journal of Medicine, 345(23), 1667–1675. blockers remain first choice in the treatment of primary hypertension? A
6
6
169. Pitt, B., Zannad, F., Remme, W. J., et al. (1999). The effect of spirono- meta-analysis. Lancet, 366, 1545–1553.
lactone on morbidity and mortality in patients with severe heart failure. 189. Moser, M. (2008). Ten years and counting: The Journal of Clinical Hy-
Randomized Aldactone Evaluation Study Investigators. New England pertension. Journal of Clinical Hypertension, 10, 333–340.
0
0
Journal of Medicine, 341(10), 709–717. 190. Staessen, J., Amery, A., & Fagard, R. (1990). Isolated systolic hyperten-
8
170. Braunwald, E., Antman, E. M., Beasley, J. W., et al. (2002). ACC/AHA sion in the elderly. Journal of Hypertension, 8, 393–405.
2002 guideline update for the management of patients with unstable 191. Qureshi, A. I., Suri, M. F., Mohammad, Y., et al. (2002). Isolated and
angina and non-ST-segment elevation myocardial infarction—Summary borderline isolated systolic hypertension relative to long-term risk and
article: A report of the American College of Cardiology/American Heart type of stroke: A 20-year follow-up of the national health and nutrition
Association task force on practice guidelines (Committee on the Man- survey. Stroke, 33(12), 2781–2788.
agement of Patients With Unstable Angina). Journal of the American Col- 192. Sagie, A., Larson, M. G., & Levy, D. (1993). The natural history of bor-
lege of Cardiology, 40(7), 1366–1374. derline isolated systolic hypertension. New England Journal of Medicine,
171. A randomized trial of propranolol in patients with acute myocardial in- 329, 1912–1917.
9
9
farction. I. Mortality results. (1982). JAMA, 247(12), 1707–1714. 193. Amery, A., Birkenyhäger, W., Brixko, P., et al. (1985). Mortality and
7
7
172. Hager, W. D., Davis, B. R., Riba, A., et al. (1998). Absence of a delete- morbidity results from the European working party on high blood pres-
rious effect of calcium-channel blockers in patients with left ventricular sure in the elderly trial. Lancet, 1, 1349–1354.
dysfunction after myocardial infarction: The SAVE Study Experience. 194. Dahlof, B., Lindholm, L. H., Hansson, L., et al. (1991). Morbidity and
SAVE Investigators. Survival and Ventricular Enlargement. American mortality in the Swedish Trial in Old Patients with Hypertension
Heart Journal, 135(3), 406–413. (STOP-Hypertension). Lancet, 338(8778), 1281–1285.